CTCE

Related by string. * * compound CTCE *

Related by context. All words. (Click for frequent words.) 66 atacicept 65 PXD# 65 AEG# 65 eniluracil 65 oral prodrug 65 JAK inhibitor 65 nucleotide analog 65 GRN#L 64 forodesine 64 PSMA ADC 64 vidofludimus 64 PEG SN# 64 phase IIa clinical 64 elotuzumab 64 Phase Ib clinical 64 Bezielle 63 ENMD 63 pomalidomide 63 IRX 2 63 preclinically 63 HGS ETR1 63 Azedra 63 Onconase 63 #ME# 63 HCV protease inhibitor 63 TOLAMBA 63 MGd 63 CBLC# 63 ONTAK 62 Traficet EN 62 R#/MEM # 62 indibulin 62 PEGPH# 62 imetelstat 62 phase Ib 62 HGS ETR2 62 ELACYT 62 obatoclax 62 PLK1 SNALP 62 Androxal TM 62 HspE7 62 MOZOBIL 62 PRT# 62 EZN 62 CCX# 62 Panzem 62 Tarvacin TM 62 menadione 62 OMP #M# 62 MEK inhibitor 62 MAXY G# 62 maturation inhibitor 61 pharmacodynamic effects 61 HGS# 61 MGCD# [001] 61 alkylating agent 61 mertansine 61 OXi# 61 Panzem R NCD 61 ofatumumab 61 Phase Ib II 61 CR# vcMMAE 61 PNP inhibitor 61 OncoVEX 61 ENMD # 61 OncoVEX GM CSF 61 phase IIb clinical 61 Exherin TM 61 NEUGENE antisense 61 IMA# 61 enzastaurin 61 Phase Ib 61 BAY #-# 61 Phase 2a trial 61 Symadex 61 EOquin TM 61 Debio 61 OvaRex ® MAb 61 orally dosed 61 HQK 61 AMD# [003] 61 Allovectin 7 R 60 rindopepimut 60 mTOR inhibitors 60 alvespimycin 60 GRNVAC1 60 Shigamabs ® 60 axitinib 60 angiogenesis inhibitor 60 Fx #A 60 pertuzumab 60 CA4P 60 OvaRex R 60 Sym# 60 Trofex 60 CEQ# 60 IND submission 60 TG# [003] 60 LEUKINE 60 Phase Ib study 60 Chemophase 60 Phase IIIb clinical 60 huN# DM1 60 HCD# [002] 60 CYT# 60 DermaVir Patch 60 AQ4N 60 ganetespib 60 OMP #R# 60 Amrubicin 60 Ozarelix 60 cilengitide 60 Aloxi injection 60 Phase 1b trial 60 HuLuc# 60 DAVANAT ® 60 Varespladib 60 Intravenous CP 60 Onco TCS 60 pharmacodynamic PD 60 urocortin 2 60 Cloretazine 60 MAGE A3 ASCI 60 NEUMUNE 60 MyVax R 60 Factor VIIa 60 Virulizin ® 60 Phase 1b 60 Fodosine 60 HCV polymerase inhibitor 60 depsipeptide 60 ISTODAX 60 Panzem R 60 pharmacodynamics 60 IMC A# 60 XmAb# 59 YONDELIS 59 Xanafide 59 tremelimumab 59 GAMMAGARD 59 subcutaneous formulation 59 mapatumumab 59 Octreotide 59 RDEA# 59 HuMax CD# 59 systemically administered 59 RSD# oral 59 Amigal 59 TOCOSOL Paclitaxel 59 PhG alpha 1 59 rhMBL 59 OHR/AVR# 59 teduglutide 59 RG# [001] 59 Phase IIa trials 59 multicenter Phase II 59 samalizumab 59 Degarelix 59 Nanobody 59 deforolimus 59 bortezomib Velcade 59 Curaxin 59 antiangiogenic 59 RGB # 59 PARP inhibitor 59 proteasome inhibitor 59 dacetuzumab 59 PRX# 59 mGluR2 NAM 59 HuMax CD4 59 Omacetaxine 59 histone deacetylase HDAC inhibitor 59 pharmacological chaperone 59 elacytarabine 59 gamma secretase inhibitor 59 velafermin belinostat 59 PANVAC VF 59 CoFactor 59 PROCHYMAL 59 IAP inhibitor 59 CINTREDEKIN BESUDOTOX 59 Hedgehog antagonist 59 PDE4 inhibitor 59 drug conjugate 59 DOS# 59 Troxatyl 59 tesmilifene 59 DXL# 59 anticancer agent 59 MT#/MEDI-# 59 multicenter Phase 59 carfilzomib 59 trodusquemine 59 Phase Ia 59 LEP ETU 59 Azixa 59 Phase 2b trial 59 Vascugel 59 Myocet 59 GAP #B# 58 velafermin 58 Insegia 58 rNAPc2 58 INCB# [001] 58 IMGN# 58 THR beta agonist 58 Phase IIB 58 AVN# [001] 58 CRLX# 58 thrombopoietin 58 otelixizumab 58 Radilex 58 TRO# 58 ISF# 58 TACI Ig 58 huC# DM4 58 vorinostat 58 VQD 58 EOquin 58 Phase #b/#a 58 ONX 58 lumiliximab 58 MEK inhibitors 58 Vidofludimus 58 EndoTAG TM -1 58 budesonide foam 58 oral antiviral 58 CYC# 58 Valortim 58 PNT# 58 belinostat 58 riociguat 58 Aganocide 58 GED aPC 58 SNS# T 58 targeted antifolate 58 pan HDAC inhibitor 58 anti angiogenic 58 MyVax ® 58 Dasatinib 58 cediranib 58 Leukine 58 Lixivaptan 58 immunomodulator 58 Cand5 58 AeroLEF TM 58 Solazed 58 Pertuzumab 58 SinuNase ™ 58 ALN TTR# 58 glucagon receptor 58 Valortim R 58 cannabinor 58 alpha#beta# integrin 58 Phase IIb clinical trials 58 ATL# [001] 58 TREANDA 58 tubulin inhibitor 58 NP2 Enkephalin 58 targeted radiotherapeutic 58 talabostat 58 Aclidinium 58 Cethrin R 58 receptor tyrosine kinase inhibitor 58 RLY# 58 SLx 58 cytoprotective 58 Cytolin ® 58 Natalizumab 58 systemic RNAi therapeutic 58 vascular disrupting agents 58 Seliciclib 58 dirucotide 58 liposomal formulation 58 lintuzumab 58 SNT MC# 58 rFIXFc 58 epothilone 58 Blinatumomab 58 FluCide 58 Cethrin 58 Tasimelteon 58 rALLy clinical trial 58 BNC# 58 sapacitabine 58 PRTX 58 Alpharadin 58 Apoptone 58 Plicera 58 novel peptide 58 Urocidin 58 VA# [002] 58 ARRY # 58 lomitapide 58 pharmacodynamic profile 58 Tavocept 58 replicon 58 Virulizin R 58 Archexin 58 CDDO Im 58 thymalfasin 58 Tyrima 58 Phase 1a clinical 58 romidepsin 58 HSP# inhibitor 58 TYZEKA 58 IMC #B 57 triphendiol 57 AP# [003] 57 molecularly targeted 57 synthetic retinoid 57 initiated Phase Ib 57 Apaziquone 57 histamine dihydrochloride 57 TOCOSOL Camptothecin 57 CB2 selective receptor agonist 57 Phase #b/#a trial 57 anti CD3 antibody 57 Fibrillex TM 57 CORT # 57 Neulasta ® 57 tyrosine kinase inhibitor 57 Aflibercept 57 Tamibarotene 57 IAP inhibitors 57 NU# [001] 57 immune modulating 57 ALN VSP 57 JAK2 inhibitors 57 Dacogen injection 57 CCR5 mAb 57 AMPK activators 57 drug GAP #B# 57 confirmatory Phase III 57 glufosfamide 57 investigational monoclonal antibody 57 Telintra 57 R#/MEM 57 humanized anti 57 orally bioavailable 57 NEUGENE 57 tanespimycin 57 lucinactant 57 AKT inhibitor 57 MYDICAR ® 57 tafamidis 57 REMUNE R 57 CytoFabTM 57 uric acid lowering 57 PCK# 57 APTIVUS 57 histone deacetylase HDAC 57 oral ridaforolimus 57 omacetaxine 57 antitumor effects 57 Allovectin 7 57 Aplidin 57 Glypromate 57 AZD# 57 verteporfin 57 ISIS # 57 Chemokine 57 apricitabine ATC 57 Protexia ® 57 HDAC Inhibitor 57 investigational humanized monoclonal antibody 57 varespladib 57 Triolex 57 HDL Mimetic Peptide 57 GLP toxicology studies 57 CBLB# 57 GnRH antagonist 57 phase IIb trial 57 safety tolerability pharmacokinetic 57 Trastuzumab 57 Phase #b/#a clinical 57 anti leukemic 57 Inhalation Solution 57 APTIVUS r 57 murine monoclonal antibody 57 DAVANAT R 57 pharmacokinetic profile 57 bevirimat 57 adecatumumab MT# 57 relapsed multiple myeloma 57 IL# PE#QQR 57 CCR2 57 Velcade bortezomib 57 Marqibo 57 refractory CLL 57 TELINTRA 57 Hsp# inhibitor 57 Alocrest 57 JAK inhibitors 57 REMINYL ® 57 Phase 2b clinical 57 selective modulator 57 Phase Ib clinical trials 57 docetaxel Taxotere R 57 initiate Phase 1b 57 personalized immunotherapy 57 entinostat 57 docetaxel chemotherapy 57 recurrent glioblastoma multiforme 57 Alferon N 57 SUTENT 57 FOLOTYN ® 57 Neuradiab 57 HDAC inhibitor 57 Irinotecan 57 Interferon alpha 57 Theratope 57 Vilazodone 57 RSD# 57 evaluating tivozanib 57 oral deforolimus 57 indolent NHL 57 thalidomide Thalomid 57 relapsed MM 57 Phase 2a clinical 57 Caprospinol 57 selective inhibition 57 trastuzumab DM1 T DM1 57 Tarvacin 57 potent antiproliferative 57 Zerenex 57 Beta catenin pathway 57 Pemetrexed 57 superficial bladder cancer 57 amrubicin 57 torezolid phosphate 57 PrevOnco ™ 57 Proxinium TM 56 Amplimexon 56 sunitinib malate 56 L Annamycin 56 haematologic malignancies 56 HuMax EGFr 56 ADP receptor antagonist 56 Talabostat 56 Curaxin CBLC# 56 metastatic CRC 56 aflibercept 56 ALV# 56 Chrysalin 56 Cotara 56 pitavastatin 56 GRN# 56 INT# [002] 56 registrational 56 SUTENT ® 56 TLR8 agonist 56 mitogen activated ERK kinase 56 VEGF receptor 56 anticancer compound 56 ALN PCS 56 Phase IIb trials 56 voreloxin 56 nanopharmaceutical 56 antiproliferative effects 56 custirsen 56 humanized antibody 56 misfolded SOD1 56 metastatic hormone refractory 56 Cloretazine R VNP#M 56 CYT# potent vascular disrupting 56 generation antisense 56 2 methoxyestradiol 56 alpha folate receptor 56 Asentar 56 ZEVALIN ® 56 estramustine 56 RNAi therapeutic targeting 56 kinase inhibitor 56 rhIL 7 56 Phase IIa clinical 56 ZACTIMA 56 Tarceva TM 56 CTA# 56 decitabine 56 Annamycin 56 ORMD 56 ALK inhibitor 56 drug ISA# 56 INTEGRILIN 56 Phase 2b study 56 brivaracetam 56 novel anticancer 56 Revlimid lenalidomide 56 metaglidasen 56 galiximab 56 lesinurad 56 novel VDA molecule 56 TRIOLEX 56 Perifosine 56 CTAP# Capsules 56 sitaxsentan 56 Elotuzumab 56 CIMZIA TM 56 non nucleoside inhibitor 56 proteasome inhibitor bortezomib 56 DR Cysteamine 56 dasatinib Sprycel 56 CD# CEA 56 HER2 positive metastatic breast 56 maribavir 56 orally administered inhibitor 56 vivo potency 56 inhibit metastasis 56 BrachySil TM 56 CCR9 antagonist 56 Elocalcitol 56 ALN TTR 56 multi kinase inhibitor 56 assessing T DM1 56 TNFerade 56 refractory gout 56 PSN# [002] 56 peripherally acting 56 Enzastaurin 56 siRNA therapeutic 56 PKC# 56 FOLOTYN 56 vascular disrupting agent 56 posaconazole 56 Phase 1a 56 ZD# [001] 56 CRMD# 56 factor G CSF 56 favorable pharmacokinetic profile 56 novel histone deacetylase 56 zanolimumab 56 MAXY alpha 56 elesclomol 56 selective androgen receptor modulator 56 small molecule Hedgehog 56 Preclinical studies suggest 56 Nasulin 56 Cloretazine ® 56 CERE 56 MyVax 56 TKM ApoB 56 BIBW 56 Pradefovir 56 polymerase inhibitor 56 PI3K inhibitor 56 compound CTCE 56 adalimumab Humira 56 Genasense ® oblimersen 56 GSK # 56 bafetinib 56 pradefovir 56 Atiprimod 56 Bicifadine 56 Clavis Pharma 56 Goserelin 56 immune modulator 56 Guanilib 56 Viprinex 56 nucleoside analog 56 FTY# 56 bendamustine 56 chemotherapy induced neutropenia 56 XL# [003] 56 Actilon 56 LHRH antagonists 56 Antiangiogenic 56 L BLP# 56 Personalized Immunotherapy 56 MDV# 56 Voreloxin 56 MNTX 56 phase IIa 56 Protexia R 56 CCR5 antagonist 56 Aurora kinase inhibitor 56 gemcitabine Gemzar ® 56 Tesmilifene 56 antitumor effect 56 vosaroxin 56 H#N# VLP vaccine 56 ganaxolone 56 ATL/TV# 56 busulfan 56 REP# 56 midstage clinical 56 PDL# 56 Targretin capsules 56 histone deacetylase inhibitor 56 monoclonal antibody 56 ProLindac 56 immune stimulatory 56 protein kinase inhibitor 56 erlotinib Tarceva ® 56 refractory prostate cancer 56 Aptivus ® 56 eTag assays 56 Maribavir 56 Ixempra 56 durable remissions 56 MEK inhibitor RDEA# 56 bone metastasis 56 FavId 56 proteasome inhibitors 56 MBP# [001] 56 pharmacokinetic PK study 56 Pathway Inhibitor 56 pharmacokinetic PK 56 Factor Xa inhibitor 56 alefacept 56 IV Busulfex 56 Pazopanib 56 BIM #A# 56 rifalazil 56 Nexavar sorafenib 56 Sprycel dasatinib 56 ThermoDox R 56 immune modulatory 56 LY# [003] 56 pediatric acute lymphoblastic 56 ongoing Phase 1b 56 perifosine KRX 56 Thiovir 55 anti CD# antibody 55 lorvotuzumab mertansine 55 MLN# 55 synthetic peptide 55 Gleevec resistant 55 IIa trial 55 AAG geldanamycin analog 55 Phenoptin 55 antitumoral 55 Sapacitabine 55 ZOLINZA 55 fibrotic disease 55 ToGA 55 paclitaxel Taxol ® 55 BEXXAR 55 microtubule inhibitor 55 vandetanib 55 Spheramine 55 docetaxel Taxotere ® 55 opioid induced bowel dysfunction 55 nanoviricide drug 55 INCB# [002] 55 generation purine nucleoside 55 receptor monoclonal antibody 55 Stedivaze 55 ADXS# 55 BioNumerik 55 Angiolix 55 myeloma cells 55 ridaforolimus 55 chemopreventive agent 55 GLPG# 55 Anavex #-# 55 selectively inhibits 55 SNT-MC#/idebenone 55 Romidepsin 55 oncolytic virus 55 dexamethasone Decadron 55 targeting CD# 55 radiation sensitizer 55 RhuDex 55 investigational therapies 55 selective kinase inhibitor 55 tiapamil 55 TLR9 agonist 55 Cloretazine R 55 Posiphen 55 antisense drug 55 QuadraSphere 55 ILLUMINATE 55 omega interferon 55 INGN 55 palifosfamide 55 UVIDEM 55 Exelixis XL# 55 LungExpress Dx TM 55 relapsed CLL 55 antitumor 55 REOLYSIN ® 55 investigational protease inhibitor 55 Azedra TM 55 VEGF Trap 55 GVAX ® 55 Dextofisopam 55 alagebrium 55 Sudhir Agrawal D.Phil 55 Phase III clinical 55 PI3K/mTOR 55 rHuPH# 55 Allovectin 7 ® 55 PEG PAL 55 inhibitory effects 55 ASONEP 55 Celator 55 Zemplar Capsules 55 telomerase inhibitor drug 55 eltrombopag 55 PEG Interferon lambda 55 methylnaltrexone 55 immunotherapeutic 55 ZK EPO 55 interferon gamma 1b 55 plasma kallikrein inhibitor 55 KNS # 55 lintuzumab SGN 55 nitazoxanide 55 lapatinib Tykerb 55 Pimavanserin 55 vWF 55 Viramidine 55 vinca alkaloid 55 milatuzumab 55 olaparib 55 apaziquone 55 NGX# 55 nicotinic alpha 7 55 Zolinza 55 antithrombotic 55 solithromycin 55 SERMs 55 PLX# 55 Phase 1b clinical 55 non nucleoside 55 ORENCIA R 55 tezampanel 55 XL# XL# 55 Oncaspar 55 Bortezomib 55 KSP inhibitor 55 bleomycin 55 EVIZON TM 55 Phase #/#a trial 55 BZL# 55 immunomodulatory properties 55 lanthanum carbonate 55 GW# [003] 55 valopicitabine 55 epothilones 55 NOD SCID mice 55 PDE# inhibitors 55 taxane chemotherapy 55 registrational trial 55 Q#IR 55 eprotirome 55 ADI PEG 55 QLT# 55 PROMACTA 55 imatinib Gleevec 55 NeuVax 55 CDK inhibitor 55 PI3K/Akt pathway inhibitor 55 DACH platinum 55 farletuzumab 55 telomerase therapeutic 55 nanoviricides 55 agonistic human 55 therapeutic monoclonal antibody 55 monoclonal antibody MAb 55 Diamyd r vaccine 55 CD# antibody [001] 55 GALNS 55 mouse xenograft models 55 sargramostim 55 VitiGam 55 IMP# 55 Epothilones 55 gastrin 55 radiolabeled monoclonal antibody 55 ponatinib 55 preclinical efficacy 55 TRV# [001] 55 AZX# 55 LHRH 55 K ras mutations 55 Cintredekin Besudotox 55 CRD5 55 Genz # 55 orBec 55 LibiGel Phase III 55 Celgosivir 55 PF # [001] 55 angiogenesis inhibition 55 UPLYSO 55 JAK1 55 Davanat 55 heavily pretreated 55 TH# [003] 55 PRX # 55 tipifarnib 55 dose escalation clinical 55 abiraterone acetate 55 pafuramidine 55 IMiD 55 DAPT 55 dosing cohort 55 Vicinium TM 55 lexidronam injection 55 tezampanel NGX# 55 phase 2a 55 BCX# 55 GSK# [001] 55 targets Galectin receptors 55 Panzem ® 54 teriflunomide 54 G CSF 54 antibody MAb 54 interferon beta 54 Quinamed 54 ABRAXANE ® 54 celgosivir 54 CAMPATH 54 AZILECT R 54 HCV polymerase 54 resolvin 54 Imprime PGG 54 NPC 1C 54 zileuton 54 imatinib therapy 54 Phase 2a 54 ataluren 54 Xcytrin 54 eculizumab 54 brentuximab vedotin SGN 54 Squalamine 54 Nanobody ® 54 Spiegelmer ® 54 Bavituximab 54 daclizumab 54 PORxin TM 54 humanized monoclonal 54 anti amnesic 54 PEP# [003] 54 Phase IIa trial 54 haematopoietic 54 omecamtiv mecarbil 54 CUDC 54 taxane 54 davunetide intranasal AL 54 Atu# 54 anti CD3 monoclonal 54 Nexavar ® 54 cancer vaccine Norelin 54 panitumumab Vectibix 54 ARRY 54 NXL# 54 cell lymphoma CTCL 54 NN# [001] 54 CD4 monoclonal antibody 54 REG2 54 Menerba 54 mTOR inhibitor 54 LHRH antagonist 54 elagolix 54 ibudilast 54 Darinaparsin 54 gemcitabine cisplatin 54 reslizumab 54 Phase IIa clinical trials 54 dexpramipexole 54 TNFa 54 Treanda 54 Potelligent Technology 54 Civacir 54 PTH analogue 54 epigenetic therapies 54 ANAVEX #-# [001] 54 signal transduction inhibitor 54 Ceplene/IL-2 54 antimetastatic 54 mg/m2 cohort 54 active moiety 54 Homspera 54 TRAIL receptor antibodies 54 erythropoietic 54 trabectedin 54 ara C 54 humanized monoclonal antibody 54 perifosine 54 TRISENOX 54 AAV2 54 RP# [002] 54 Ophena 54 Phase 1b clinical trials 54 Anthim 54 mTOR inhibition 54 sorafenib Nexavar 54 IgG1 monoclonal antibody 54 Aurexis 54 IFN beta 54 Erbitux cetuximab 54 CINOD 54 dose escalation study 54 xenograft models 54 PARP inhibition 54 elvucitabine 54 JAK3 54 picoplatin 54 intratumoral injection 54 TBC# 54 CD# monoclonal antibody 54 IGF IR 54 octreotide 54 PS# [001] 54 Alfimeprase 54 E1 INT TM 54 BiTE antibody 54 trabedersen 54 pharmacodynamic markers 54 Vidaza azacitidine 54 Temsirolimus 54 Aurora kinase 54 TOCOSOL 54 Reolysin 54 BrachySil ™ 54 preclinical studies 54 DNA hypermethylation 54 LT NS# 54 pharmacodynamic 54 gemcitabine Gemzar 54 Revimmune 54 acute GvHD 54 Evoltra 54 ON #.Na 54 TKM PLK1 54 NTDDS 54 radiotherapeutic 54 MAb 54 exon skipping 54 cethromycin 54 regorafenib 54 TransVax tm 54 OncoVex 54 demethylating agents 54 CTLA 4 54 DEB# 54 phase IIb 54 PDX pralatrexate 54 Neo Kidney Augment 54 cancer immunotherapies 54 Vandetanib 54 KRN# 54 Anidulafungin 54 EndoTAG 54 MEND CABG II 54 luteinizing hormone releasing 54 Tocosol Paclitaxel 54 immunomodulatory 54 Methylnaltrexone 54 Ontak 54 dose cohorts 54 JAK#/JAK# inhibitor CYT# 54 bardoxolone 54 Hsp# Inhibitor 54 bevacizumab Avastin ® 54 IFN alpha 54 small molecule defensin 54 mu opioid receptor antagonist 54 pralatrexate 54 novel peptides 54 Valortim ® 54 Tesetaxel 54 dose escalation Phase 54 OvaRex 54 ONCONASE 54 AAV vector 54 Vivecon 54 5 HT6 antagonist 54 ESTRASORB 54 antitumor efficacy 54 cetuximab Erbitux R 54 veltuzumab 54 camptothecin 54 BRAF V# mutation 54 relapsing remitting multiple sclerosis 54 MORAb 54 TroVax ® 54 delta isoform 54 sodium Injection 54 vilazodone 54 Aplidin R 54 pazopanib 54 bevasiranib 54 oral proteasome inhibitor 54 Tarsa oral calcitonin 54 preclinical 54 blinatumomab 54 EGFR HER2 54 relapsed ovarian cancer 54 telaprevir dosed 54 highly selective inhibitor 54 tolerability pharmacokinetics 54 MT# MEDI 54 protein tyrosine phosphatase 1B 54 Mipomersen 54 DermaVir 54 neratinib

Back to home page